about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

ADC Ther­a­peu­tics sells off roy­al­ty share for lead an­ti­body-drug con­ju­gate in $325M deal

4 years ago
Deals

Mer­ck­'s 15-strain pneu­mo­nia shot match­es Pre­vnar 13 in late-stage in­fant study, but Pfiz­er's next-gen shot looms

4 years ago
R&D
Pharma

Re­gen­eron earns mid-stage win for high­er dose of Eylea, hop­ing to re­fresh its sales pitch

4 years ago
R&D
Pharma

Ther­a­vance takes a gut punch as J&J-part­nered JAK drug flops key test in ul­cer­a­tive col­i­tis

4 years ago
R&D

Cara, Vi­for Phar­ma score speedy FDA nod on itch­ing drug for CKD — shares surge

4 years ago
Pharma
FDA+

Pfiz­er earns long-await­ed full FDA nod for Covid-19 vac­cine, a hope­ful aid in US cam­paign

4 years ago
FDA+
Coronavirus

Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

4 years ago
Deals

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

4 years ago
R&D
Cell/Gene Tx

J&J's Alex Gorsky set to step away from CEO role, hand­ing the reins to Covid-19 czar Joaquin Du­a­to

4 years ago
People
Pharma

CSL's Se­qirus, spurred on by Covid-19 mR­NA vac­cines, props up new unit for 'self-am­pli­fy­ing' shot tech

4 years ago
Pharma

Sesen Bio tri­al marred by mis­con­duct — re­port; Bris­tol My­ers picks up de­vel­op­ment of AI out­fit's im­munol­o­gy drug

4 years ago
News Briefing

Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy ...

4 years ago
Pharma

In­side the deal: Sanofi flipped from sell-off to merg­er in lead up to $3.2B Trans­late buy­out

4 years ago
Deals

FDA lifts clin­i­cal hold on Rock­et's gene ther­a­py for heart fail­ure af­ter 3-month de­lay

4 years ago
Cell/Gene Tx
FDA+

Mer­ck takes home an FDA win for a Roger Perl­mut­ter fa­vorite, po­ten­tial­ly crack­ing open big mar­ket

4 years ago
R&D
FDA+

Longeveron's cell ther­a­py flops ear­ly walk test study as ex­ecs tout flim­sy sup­port­ing da­ta

4 years ago
Cell/Gene Tx

Drug pric­ing dis­rup­tor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

4 years ago
Financing
Deals

Chi­nese start­up with Mer­ck vet at the helm ac­quires rights to Oys­ter Point's eye dis­ease nasal spray

4 years ago
Deals
China

Dicer­na's RNAi drug shows 'in­con­sis­ten­t' re­sults in rare kid­ney dis­ease, tank­ing shares de­spite tri­al win

4 years ago
R&D

Mer­ck­'s Keytru­da takes home ad­ju­vant win in melanoma, es­ca­lat­ing ear­ly-line fight with Bris­tol My­ers

4 years ago
R&D
Pharma

Zymer­gen's sud­den im­plo­sion shocked biotech. A lin­ger­ing loan could make things even worse

4 years ago
Financing

Saman­tha Du's Zai Lab inks sur­pris­ing re­search col­lab with Schrödinger for DNA dam­age drug

4 years ago
Deals
R&D

Syn­bio uni­corn Zymer­gen jet­ti­sons found­ing CEO, cuts guid­ance as cus­tomers re­port lead prod­uct does­n't work

4 years ago
People
R&D

Eli Lil­ly: As do­nanemab fil­ing ap­proach­es, ex­ecs 'even more con­fi­den­t' in da­ta pack­age

4 years ago
R&D
Pharma
First page Previous page 567891011 Next page Last page
A service from the Financial Times